新闻
15 小时之前
AACR会议
15 小时之前
Enterome receives FDA Fast Track designation in follicular lymphoma for lead OncoMimics™ immunotherapy EO2463
免疫疗法快速通道临床结果
16 小时之前
Aicuris Announces Pritelivir Met Primary Endpoint in Immunocompromised Patients with Refractory Herpes Simplex Virus in Phase 3 Pivotal Trial
临床结果合格传染病产品突破性疗法
16 小时之前
细胞疗法临床申请免疫疗法临床研究
16 小时之前
引进/卖出免疫疗法
17 小时之前
Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)
临床结果上市批准
18 小时之前
Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor
临床结果申请上市
BPGbio Presents Phase 2 Glioblastoma Data on BPM31510 at ESMO 2025
孤儿药临床结果
临床结果
Amphista Therapeutics nominates AMX-883, an orally available Targeted Glue™ degrader of BRD9, as its first clinical development candidate for the treatment of acute myeloid leukaemia
蛋白降解靶向嵌合体高管变更